Framework agreement for the supply of four medicines

Summary

Amgros is procuring four medicines under framework agreements for delivery to hospital pharmacies and Amgros warehouses in Denmark. The four lots cover ravulizumab infusion solution, pegcetacoplan infusion solution, crovalimab injection or infusion solution, and 200 mg iptacopan hard capsules. The estimated total value is DKK 525 million, and the maximum total value of the framework agreements is DKK 1.05 billion. The planned contract period is 1 May 2027 to 30 April 2030; the ordinary purchasing period is 1 May 2027 to 30 April 2028, with up to two extensions of up to 12 months each.